Clinical Trails

An ongoing phase 1b/2a clinical trial is showing encouraging early results for Nadunolimab combined with azacitidine in patients with high-risk myelodysplastic syndrome (MDS), and with azacitidine plus Venetoclax in relapsed or refractory acute myeloid leukemia (AML). The investigator-initiated study, conducted at MD Anderson Cancer Center, has completed its phase 1b dose-escalation stage without any dose-limiting […]

An analysis of reconstructed individual patient data from the phase 3 EORTC 1333/PEACE-3 trial found that combining Enzalutamide with Radium-223 produced a delayed but meaningful long-term survival benefit in patients with metastatic castration-resistant prostate cancer (mCRPC). Researchers reported that the combination showed little survival advantage during the first 18 months of active treatment, but benefits

Blinded results from Part A of the phase 2b/3 MIRACLE trial showed encouraging activity for Annamycin combined with Cytarabine in patients with relapsed or refractory Acute Myeloid Leukemia receiving second-line treatment. The study compared the combination with cytarabine plus placebo in patients aged 18 to 80. Among 45 evaluable patients, the pooled composite complete remission

A phase 2 trial found that combining Camrelizumab and Apatinib showed promising results in patients with refractory chordoma, a rare and aggressive spine cancer. The study included 33 patients. The combination achieved an objective response rate of 24.2% by RECIST 1.1 and 48.5% by Choi criteria, with a disease control rate of 90.9%. Median progression-free

Results from the phase 3 PSMAddition trial showed that adding lutetium Lu 177 vipivotide tetraxetan (Pluvicto) to androgen-deprivation therapy (ADT) and an androgen receptor pathway inhibitor (ARPI) improved prostate-specific antigen (PSA) responses in patients with metastatic hormone-sensitive prostate cancer (mHSPC). The randomized phase 3 study included 1,144 men with PSMA-positive mHSPC. Patients received either Pluvicto

A Phase 2 randomized study found that giving two preoperative doses of intravesical mitomycin-C before TURBT significantly reduced recurrence and progression in patients with non–muscle-invasive bladder cancer. The strategy is based on the idea that tumor manipulation during surgery can release cancer cells that later reimplant in the bladder. By administering chemotherapy before surgery, while

Interim results showed that detalimogene voraplasmid, a non-viral intravesical gene therapy, demonstrated encouraging activity and safety in patients with high-risk, BCG-unresponsive non–muscle-invasive bladder cancer who had already received extensive prior treatment. Among 125 evaluable patients, 54% achieved a complete response at some point during treatment, and most responses were seen by the first two-month assessment.

High-level results from the phase 3 VOLGA trial show that combining durvalumab (Imfinzi) with enfortumab vedotin (Padcev) before surgery significantly improves survival for patients with muscle-invasive bladder cancer who cannot receive or choose not to receive cisplatin chemotherapy. The treatment improved both event-free survival and overall survival compared with surgery alone. Another treatment group using

A Phase 1/2 study found that combining Belantamab mafodotin with the KRd regimen (carfilzomib, lenalidomide, and dexamethasone) produced strong and durable responses in patients with relapsed or refractory multiple myeloma. Researchers tested a new dosing schedule for belamaf, giving the drug every eight weeks instead of every three weeks to reduce eye-related side effects while

Interim results from the Phase 2 HexAgon study showed that adding the OX40 agonist INBRX-106 to Keytruda improved outcomes for patients with advanced head and neck squamous cell carcinoma (HNSCC). The combination treatment achieved a confirmed overall response rate of 44%, compared with 21.4% for Keytruda alone. Three patients receiving the combination therapy had a